Compare Cassava Sciences Inc (FLNA) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Monster Beverage Corp — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Monster Beverage Corp trades at $99.75 (market cap $95.42B). The key difference: Monster Beverage Corp is far larger — about 1795.6× Cassava Sciences Inc's market cap, and Monster Beverage Corp is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | MNST | |
|---|---|---|
Market Cap | $53.14M | $95.42B |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $98.01 |
52-Week Low | $1.09 | $58.65 |
Enterprise Value | -$33.43M | $93.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Monster Beverage (MNST) trades at $98.005, up 0.96% on the day, with a bullish technical signal and strong fundamental performance. The company has consistently beaten earnings expectations for the last three quarters, with Q1 2026 EPS of $0.58 beating estimates of $0.527. Revenue growth is robust, increasing from $6.3B in 2022 to $8.3B in 2025, while net profit margins have expanded to 23.11%. A 2-for-1 stock split was recently announced, effective August 11, 2026.
The outlook remains positive driven by international expansion and product innovation, with 45% of sales now from overseas. Key risks include premium valuation multiples (P/E of 47.14) and competitive pressure in the energy drink sector. Analyst consensus is 'Buy' with a $94.60 price target, though the current price trades slightly above this target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
